Table 1 Baseline data
From: A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
Total Number of patients | 16 |
Males | 11 |
Females | 5 |
Median age | 59 years (range 44–68) |
Previous therapy (number of patients) | |
Nephrectomy | 8 |
Interferon | 9 |
Hormone therapy (megesterol/medroxyprogesterone) | 4 |
Radiotherapy | 6 |
Time from diagnosis to systemic therapy (number of patients) | |
0–24 months | 13 |
⩾24 months | 3 |
Baseline WHO performance status (number of patients) | |
Zero | 8 |
One | 5 |
Two | 3 |
Total number of bryostatin-1 infusions | 181 (median 12 (range 1–29)) |
